
OUR FOCUS
Committed to Successful Outcomes
One of the Healthcare industry’s most active subsectors, Biopharma draws strong corporate and investor interest in the development of novel medicines to treat significant unmet medical needs. Having a reliable, ongoing source of capital is key to funding the lengthy process of bringing therapies to market.
Investors and corporate clients repeatedly turn to Leerink Partners’ experience and expertise to unlock the growth potential of innovative biopharma companies.
Recent transactions

$500 Million
Exclusive Financial Advisor
Term Loan Facility
April 2025

$200 Million
Joint Bookrunner
Follow-On
April 2025

$18.8 Million
Joint Bookrunner
Follow-On
March 2025

$50 Million
Joint Bookrunner
Follow-On
March 2025
Featured Insights

Articles
April 2025
The US Gets Entresto® for a Steal

Podcasts
April 2025
Head of U.S. Public Affairs and Patient Advocacy, Oncology with Sanofi, Elizabeth Franklin, PhD, MSW

Featured Research
April 2025